• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds
CMECNE

Antiepileptic Drugs: What is the Impact on Risk for Birth Defects

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. State which AEDs are most highly associated with major congenital malformations
2. Discuss reasons why, based on the results of this study, providers should be cautious in the use of VPA in pregnancy

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

BACKGROUND AND PURPOSE:

  • Most women with epilepsy will continue to take antiepileptic drugs (AEDs) throughout pregnancy based on medical advice and the balance of risks/benefits
  • Weston et al. (Cochrane Database Syst Rev, 2016) examined the AED exposure and prevalence of congenital malformations in offspring

METHODS:

  • Systematic review and meta-analysis
  • Relevant literature included prospective cohort studies, RCTs and registry studies
  • Intervention group
    • Women with epilepsy receiving AEDs as monotherapy
  • Control groups
    • Women without epilepsy
    • Women with epilepsy not on treatment
  • Primary outcome
    • Presence of a major congenital malformation
  • Secondary outcome
    • Specific types of major congenital malformation (NTDs, cardiac defects, orofacial clefting/craniofacial anomalies and skeletal or limb malformations)
    • Minor malformations (e.g., low set ears or digital hypoplasia)

RESULTS:

Risk of Malformation

  • 50 studies were selected, 31 of which contributed to meta-analysis
  • Carbamazepine (CBZ): Increased risk of malformation vs controls
    • Without epilepsy: Risk ratio (RR) 2.01, 95% confidence interval (CI) 1.20 to 3.36
    • Untreated epilepsy: RR 1.50, 95% CI 1.03 to 2.19)
  • Phenobarbital (PB): Increased risk of malformation vs control
    • Without epilepsy: RR 2.84, 95% CI 1.57 to 5.13
  • Phenytoin (PHT): Increased risk of malformation vs controls
    • Without epilepsy: RR 2.38, 95% CI 1.12 to 5.03
    • Untreated epilepsy: RR 2.40, 95% CI 1.42 to 4.08)
  • Topiramate (TPM): Increased risk of malformation vs control
    • Without epilepsy: RR 3.69, 95% CI 1.36 to 10.07
  • Valproate (VPA): Increased risk of malformation vs controls
    • Without epilepsy: RR 5.69, 95% CI 3.33 to 9.7
    • Untreated epilepsy: RR 3.13, 95% CI 2.16 to 4.54)
  • No increased risk of malformations for the following (limited data for meds with *)
    • Lamotrigine (LTG)
    • *Gabapentin (GBP)
    • *Levetiracetam (LEV)
    • *Oxcarbazepine (OXC)
    • *Primidone (PRM)
    • *Zonisamide (ZNS)

Prevalence of Major Malformations

  • CBZ: 4.93% (95% CI 3.84 to 6.16)
  • GBP: 1.47% 1.47% (95% CI 0.26 to 3.64)
  • LEV: 1.77% 1.77% (95% CI 0.98%-2.79)
  • LTG: 2.31% (95% CI 1.87 to 2.78)
  • OXC: 2.39% (95% CI 0.85% to 4.68%)
  • PB: 7.10% (95% CI 5.36 to 9.08)
  • PHT: 6.26% (95% CI 4.37 to 8.47)
  • PRM: 8.49% (95% CI 4.13 to 14.22)
  • TPM: 4.28% (95% CI 2.65 to 6.29)
  • VPA: 10.93% (95% CI 8.91 to 13.13)
  • ZNS: 0.28% (95% CI 0.25 to 2.39) / only 1 small study

Comparing AEDs

  • VPA: increased risk of malformation compared to
    • CBZ: RR 2.44, 95% CI 2.00 to 2.94
    • GBP: RR 6.21, 95% CI 1.91 to 20.23
    • LEV: RR 5.82, 95% CI 3.13 to 10.81)
    • LTG: RR 3.56, 95% CI 2.77 to 4.58
    • TPM: RR 2.35, 95% CI 1.40 to 3.95
    • OXC: RR 3.71, 95% CI 1.65 to 8.33
    • PB: RR 1.59, 95% CI 1.11 to 2.29
    • PHT: RR 2.00, 95% CI 1.48 to 2.71
    • ZNS: RR 17.13, 95% CI 1.06 to 277.48
  • CBZ: increased risk of malformation compared to
    • LEV: RR 1.84, 95% CI 1.03 to 3.29
    • LTG: RR 1.34, 95% CI 1.01 to 1.76
  • PB: Increased risk of malformation compared to
    • GBP: RR 8.33, 95% CI 1.04 to 50.00
    • LEV: RR 2.33, 95% CI 1.04 to 5.00
    • LTG: RR 3.13, 95% CI 1.64 to 5.88)
  • PHT: Increased risk of malformation compared to
    • LTG: RR 1.89, 95% CI 1.19 to 2.94
  • TPM: Increased risk of malformation compared to
    • LEV: RR 2.00, 95% CI 1.03 to 3.85
    • LTG: RR 1.79, 95% CI 1.06 to 2.94

Specific Malformations

  • PB exposure was associated with cardiac malformations
  • VPA exposure with NTD, cardiac, clefting/craniofacial anomalies, and skeletal and limb malformations
  • Risk of malformation was dosage dependent for VPA exposure
  • Limited data may have contributed to lack of statistically significant associations with specific malformations in other AEDs

CONCLUSION:

  • AEDs are associated with increased risk of congenital malformation in children, with VPA ranking the highest risk and LEV and LTG the lowest
    • Concurs with previous studies and professional guidelines to be cautious using VPA
    • NOTE: Consider higher dose of folic acid (4mg daily) for women on VPA
  • Further studies are needed to define specific malformations associated with LEV and LTG
  • Few studies provided sufficient data on minor malformations

Learn More – Primary Sources:

Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Take a post-test and get CME credits

TAKE THE POST TEST

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Adverse Perinatal Outcomes and Epilepsy: Is it the Disorder or the Treatment?
Vitamin B3 (Niacin) and its Role in Preventing Birth Defects
Practical obstetrics info for your women's healthcare practice
Cleft Lip and Palate – Considerations and Discussion Points
NTDs and Pregnancy – Folic Acid Recommendations

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site